Literature DB >> 29673923

CRISPR/Cas9 for cancer research and therapy.

Tianzuo Zhan1, Niklas Rindtorff2, Johannes Betge1, Matthias P Ebert3, Michael Boutros4.   

Abstract

CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CRISPR; Cancer; Cas9; Genome-engineering; High-throughput screening; Immune therapy; Organoids; Synthetic lethality

Mesh:

Year:  2018        PMID: 29673923     DOI: 10.1016/j.semcancer.2018.04.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  67 in total

1.  Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

Authors:  Masoud Nasri; Perihan Mir; Benjamin Dannenmann; Diana Amend; Tessa Skroblyn; Yun Xu; Klaus Schulze-Osthoff; Maksim Klimiankou; Karl Welte; Julia Skokowa
Journal:  Blood Adv       Date:  2019-01-08

Review 2.  Recent advances in liposome formulations for breast cancer therapeutics.

Authors:  Biyao Yang; Bo-Ping Song; Shaina Shankar; Anna Guller; Wei Deng
Journal:  Cell Mol Life Sci       Date:  2021-05-11       Impact factor: 9.261

Review 3.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03

Review 4.  The emerging role of long noncoding RNAs in esophageal carcinoma: from underlying mechanisms to clinical implications.

Authors:  Siyuan Luan; Yushang Yang; Yuxin Zhou; Xiaoxi Zeng; Xin Xiao; Bo Liu; Yong Yuan
Journal:  Cell Mol Life Sci       Date:  2021-01-19       Impact factor: 9.261

5.  Paxillin family of focal adhesion adaptor proteins and regulation of cancer cell invasion.

Authors:  Kyle M Alpha; Weiyi Xu; Christopher E Turner
Journal:  Int Rev Cell Mol Biol       Date:  2020-08-06       Impact factor: 6.813

Review 6.  In Vivo Imaging with Genetically Encoded Redox Biosensors.

Authors:  Alexander I Kostyuk; Anastasiya S Panova; Aleksandra D Kokova; Daria A Kotova; Dmitry I Maltsev; Oleg V Podgorny; Vsevolod V Belousov; Dmitry S Bilan
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

7.  CRISPR/Cas9 library screening uncovered methylated PKP2 as a critical driver of lung cancer radioresistance by stabilizing β-catenin.

Authors:  Chun Cheng; Xiaofeng Pei; Si-Wei Li; Jun Yang; Chenxi Li; Jianjun Tang; Kaishun Hu; Guofu Huang; Wei-Ping Min; Yi Sang
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

Review 8.  Vector engineering, strategies and targets in cancer gene therapy.

Authors:  Vijayata Singh; Nusrat Khan; Giridhara R Jayandharan
Journal:  Cancer Gene Ther       Date:  2021-04-15       Impact factor: 5.987

Review 9.  CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.

Authors:  Xuejin Ou; Qizhi Ma; Wei Yin; Xuelei Ma; Zhiyao He
Journal:  Front Cell Dev Biol       Date:  2021-05-20

10.  ITGB6-Knockout Suppresses Cholangiocarcinoma Cell Migration and Invasion with Declining PODXL2 Expression.

Authors:  Yurie Soejima; Miho Takeuchi; Nao Miyamoto; Motoji Sawabe; Toshio Fukusato
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.